Drugs / Pfs230D1M-EPA/AS01
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03917654 | Apr 2019 → Jul 2021 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pfs230D1M-EPA/AS01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03917654 ↗ |
| Known as | Pfs230D1M-EPA | “The next step in the development of Pfs230D1M-EPA as a TBV is therefore to conduct an age de-escalation trial” NCT03917654 ↗ |
| Modality | Vaccine | “transmission-blocking vaccine (TBV)” NCT03917654 ↗ |